Hämostaseologie, Table of Contents Hamostaseologie 1997; 17(03): 156-157DOI: 10.1055/s-0038-1659981 Originalarbeiten/Original Articles Schattauer GmbH The Management of Patients with Atrial Fibrillation Michael D. Ezekowitz 1 Yale University School of Medicine, New Haven, USA › Author Affiliations Recommend Article Abstract Buy Article Full Text References REFERENCES 1 Peterspun P.M.D. et al. Placebo-Controlled, Randomized Trial of Warfarin And Aspirin for Prevention of Thromboembolic Complications in Chronic Atrial Fibrillation: The Copenhagen AFASAK Study. Lancet 1989; 1: 175-8. 2 The Boston Area Trial for Atrial Fibrillation Investigators. The Effect of Low Dose Warfarin on the Risk of Stroke in Patients with Nonrheumatic Atrial Fibrillation. N Engl J Med 1990; 323: 1505. 3 Connolly S.J, Laupacis A, Gent M. et al. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol 1991; 18: 349-55. 4 Stroke Prevention in Atrial Fibrillation Investigators. Stroke Prevention in Atrial Fibrillation Study; Final Results. Circulation 1991; 84: 527-39. 5 Ezekowitz M.D, Bridgers S.L, James K.E, Carliner N.H, Colling C.L, Gornick C.C. et al. And SPINAF Investigators. Warfarin in the Prevention of Stroke Associated with Non-rheumatic Atrial Fibrillation. N Engl J Med 1992; 327: 406-12. 6 Atrial Fibrillation Investigators. Risk Factor for Stroke and Efficacy of Antithrombotic Therapy in Atrial Fibrillation; Analysis of Pooled Data From Five Randomized Controlled Trials. Arch Intern Med 1994; 154: 1449-58. 7 Stroke Prevention in Atrial Fibrillation Investigators. Adjusted -dose Warfarin Versus Low-Intensity, Fixed-Dose Warfarin Plus Aspirin for High-Risk Patients with Atrial Fibrillation: Stroke Prevention in Atrial Fibrillation III Randomized Clinical Trial. Lancet 1996; 348: 633-8.
